Back to discover
Drug
Rebimastat
Late-stage clinical developmentClassMatrix metalloproteinase 9 inhibitor
6
Protein targets
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this drug.
Clinical trial2013-06-05Completed · ClinicalTrials.gov
A Phase I-II Trial Of BMS-275291 In Patients With HIV-Related Kaposi's Sarcoma
Clinical trial2013-02-11Completed · ClinicalTrials.gov
Clinical trial2013-02-01Completed · ClinicalTrials.gov
Clinical trial2009-02-10Completed · ClinicalTrials.gov
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Canonical name
Rebimastat
RxNorm CUI
620506
ChEMBL ID
CHEMBL76222
UNII
1B47R6ZX4K
Primary mechanism
Matrix metalloproteinase 9 inhibitor
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY4
registered trials across all phases
LATEST COMPLETION 2009
1
Late-stage (III+)
4
Completed
PHASE DISTRIBUTIONn = 4
Phase 1 / 21Phase 22Phase 2 / 31
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
CompletedPH II
References & data sources
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- ClinicalTrials.gov — clinical trials